CBD Life Sciences, Inc. (OTC Pink: CBDL), through its subsidiary, LBC Bioscience, Inc., is actively engaged in the emerging hemp CBD market. Specifically, LBC Bioscience is focused on developing and marketing a line of organic, cannabinoid-based products: hemp drops, massage oil, pain relief creams, supplements, edibles, pet products, anxiety/sleep products, and more. Shares of the CBD company are surging 71%, through early trading on Thursday, April 18, 2019. Over the past month, CBD Life Sciences has seen average daily volume of 232,248 shares. However, volume of 2.23 million shares or dollar volume of $32,335, has already exchanged hands through early trading on Thursday.
Shares of CBD Life Sciences are soaring on Thursday, after the company announced that its subsidiary, LBC Bioscience, has entered into negotiations to distribute its products across Japan. The company estimates that negotiations could close within the next two weeks and with an initial order of $250,000. The Japanese CBD market is experiencing high-growth, which is seeing nearly 100% year-over-year growth and annual sales of over $10 billion. Here is the full press release detailing of the Japanese market negotiations:
CBD Life Sciences, Inc. Press Release:
SCOTTSDALE, ARIZONA, April 18, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — CBD Life Sciences Inc. (OTC:CBDL) is pleased to announce that its wholly owned subsidiary, LBC Bioscience has entered into negotiations to distribute its line of products in Japan. The negotiations are anticipated to close within the next two weeks with an initial order of $250,000.
Japan’s market for CBD products is growing at almost 100% year-over-year with annual supplement sales valued at over $10 billion. Japan’s consumer economy is very health conscious, sophisticated, comprised of an aging population with an early adoption of CBD nutraceuticals.
“We are very excited about this opportunity to enter the Japanese market,” commented Lisa Nelson, President & CEO of CBD Life Science. “The Japanese have embraced the benefits of CBD and we want to be on the forefront providing quality products to this aggressive expanding market,” continued Ms. Nelson.
About CBD Life Sciences Inc.
CBD Life Sciences Inc. is a publicly traded company having its common shares quoted on the OTC Markets under the symbol ‘CBDL’. The Company’s main focus is to identify, evaluate and acquire undervalued opportunities with the objective of increasing shareholder value. The acquisition of LBC Bioscience Inc. is the first in the CBD space and the company is actively searching for additional opportunities within this emerging sector.
About LBC Bioscience Inc.
LBC Bioscience Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. LBC is developing and marketing a line of cannabidiol based organic products such as hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions, supplements, edibles, and a full line of pet products. In addition, LBC is in the process of developing an anti-aging skin product line. LBC’s products can be viewed and purchased on the company’s website at www.lbcbioscienceinc.com.
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See Optium Cyber Systems, Inc.’s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management’s current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
The post CBD Life Sciences, Inc. (OTC Pink: CBDL) Surges 71% After Negotiations to Enter Japanese Market appeared first on Spotlight Growth.
Source: SpotLight Growth Canabis
CBD Life Sciences, Inc. (OTC Pink: CBDL) Surges 71% After Negotiations to Enter Japanese Market
SpotLight Growth Canabis